Nephros (NASDAQ: NEPH) posts updated 2026 corporate presentation online

Q: What did Nephros (NEPH) disclose in its June 12, 2026 8-K?

Nephros disclosed that it posted an updated 2026 Corporate Presentation on its corporate website. The presentation is attached to the current report as Exhibit 99.1 and is furnished for informational purposes.

Q: Where can investors find the Nephros (NEPH) 2026 Corporate Presentation?

The 2026 Corporate Presentation is available on Nephros’s corporate website and is also included with the current report as Exhibit 99.1 . The company specifically notes this exhibit as the updated 2026 presentation.

Q: What exhibits are included with the Nephros (NEPH) June 12, 2026 report?

Nephros includes two exhibits: Exhibit 99.1 , the Nephros, Inc. 2026 Corporate Presentation, and Exhibit 104 , the cover page interactive data file embedded within the Inline XBRL document.

Q: Who signed the Nephros (NEPH) June 12, 2026 current report?

The report was signed on behalf of Nephros, Inc. by Judy Krandel , who is identified as the company’s Chief Financial Officer . The signature block confirms she signed as a duly authorized officer.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Nephros, Inc. furnished an updated 2026 Corporate Presentation on its website on June 12, 2026, and attached it as Exhibit 99.1 to a current report. The presentation is provided as public information but is designated as “furnished,” meaning it is not treated as formally filed under the securities laws or automatically incorporated into other registration or reporting documents.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Terms

Emerging growth company, corporate presentation, Exchange Act, Inline XBRL

4 terms

Emerging growth company regulatory

"Emerging growth company On June 12, 2026, Nephros, Inc."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

corporate presentation financial

"posted an updated 2026 Corporate Presentation on its corporate website."

Exchange Act regulatory

"for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)"

A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.

Inline XBRL technical

"Cover Page Interactive Data File (embedded M2 Compliance within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/12/2026 - 05:43 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2026

NEPHROS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		001-32288		13-3971809
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

380 Lackawanna Place, South Orange, New Jersey 07079

(Address of principal executive offices, including ZIP code)

(201) 343-5202

(Registrant’s telephone number, including area code)

n/a

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		NEPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.

Regulation FD Disclosure.

On June 12, 2026, Nephros, Inc. (the “Company”) posted an updated 2026 Corporate Presentation on its corporate website. A copy of this presentation is furnished herewith as Exhibit 99.1.

Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 7.01 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

Item 9.01.

Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.		Description
99.1		Nephros, Inc. 2026 Corporate Presentation.
104		Cover Page Interactive Data File (embedded M2 Compliance within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nephros, Inc.

Dated: June 12, 2026	By:	/s/ Judy Krandel
		Judy Krandel
		Chief Financial Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Nephros (NEPH) disclose in its June 12, 2026 8-K?

Nephros disclosed that it posted an updated 2026 Corporate Presentation on its corporate website. The presentation is attached to the current report as Exhibit 99.1 and is furnished for informational purposes.

Where can investors find the Nephros (NEPH) 2026 Corporate Presentation?

The 2026 Corporate Presentation is available on Nephros’s corporate website and is also included with the current report as Exhibit 99.1. The company specifically notes this exhibit as the updated 2026 presentation.

Is the Nephros (NEPH) 2026 Corporate Presentation considered filed with the SEC?

No. Nephros states the presentation in Exhibit 99.1 and the related disclosure are furnished, not filed, under the securities laws. This means they are not subject to Section 18 filing liability or automatically incorporated into other filings.

What exhibits are included with the Nephros (NEPH) June 12, 2026 report?

Nephros includes two exhibits: Exhibit 99.1, the Nephros, Inc. 2026 Corporate Presentation, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Nephros (NEPH) June 12, 2026 current report?

The report was signed on behalf of Nephros, Inc. by Judy Krandel, who is identified as the company’s Chief Financial Officer. The signature block confirms she signed as a duly authorized officer.

Filing Exhibits & Attachments

36 documents